Clinical pharmacology of coronary thrombolysis.

Abstract

Pharmacologic thrombolysis is dependent on activation of endogenous plasminogen to the active proteolytic enzyme, plasmin. Agents such as tissue-plasminogen activator with a high affinity for fibrin bound plasminogen result in high local concentration of plasmin. Thus, they achieve clot lysis with less tendency to induce a systemic lytic state reflecting extensive fibrinogenolytic activity in the circulation. Appropriate dose regimens for thrombolytic agents in specific clinical situations is critical to maximize therapeutic efficacy while minimizing the risk of significant bleeding.

• Authors: A I Tiefenbrunn, A K Robison, B E Sobel
• Journal: Cardiology clinics (Cardiol Clin) Vol. 5 Issue 1 Pg. 125-8 (Feb 1987) ISSN: 0733-8651 [Print] Netherlands
• PMID: 3103917 (Publication Type: Journal Article, Research Support, U.S. Gov't, P.H.S.)

Chemical References

• Fibrinolytic Agents
• Streptokinase
• Tissue Plasminogen Activator

Topics

• Coronary Disease (drug therapy)
• Coronary Thrombosis (drug therapy)
• Fibrinolytic Agents (administration & dosage, pharmacology, therapeutic use)
• Humans
• Myocardial Infarction (drug therapy)
• Streptokinase (therapeutic use)
• Tissue Plasminogen Activator (therapeutic use)